ALX Oncology Holdings Inc. Common Stock
ALXOALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies that target immune evasion mechanisms in cancer. The company’s lead program aims to improve outcomes for patients by restoring the immune system’s ability to fight tumors. Headquartered in the United States, ALX Oncology is dedicated to advancing research and development in immuno-oncology.
Company News
ALX Oncology announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, with CEO Jason Lettmann and CMO Barbara Klencke delivering a corporate presentation on January 15, 2026. The clinical-stage biotech company is advancing evorpacept, a CD47-inhibitor being evaluated across multiple cancer indications, and ALX2004, an EGF...
ALX Oncology reported impressive results from a Phase 2 trial combining evorpacept with rituximab and lenalidomide in treating indolent non-Hodgkin lymphoma, achieving a 92% complete response rate and 100% overall response rate.
The HER2-positive gastric cancer market is experiencing sustained growth, with over 20 companies developing novel targeted therapies, driven by advances in precision medicine and expanded HER2 testing.
ALX Oncology will participate in two healthcare conferences in November and December 2025, presenting their ongoing clinical-stage cancer therapies, including lead candidate evorpacept and new pipeline candidate ALX2004.
Revolution Medicines appointed Alan Sandler, M.D. as chief development officer and added regional general managers in the U.S. and Europe to support potential approvals of RAS-targeted cancer therapies.
